Publikationen, an denen er mitarbeitet María Luisa Sanz Larruga (40)

2016

  1. Basophil activation testing in diagnosis and monitoring of allergic disease - An overview

    Allergo Journal, Vol. 25, Núm. 4, pp. 26-33

  2. Basophil activation testing in diagnosis and monitoring of allergic disease – an overview

    Allergo Journal International, Vol. 25, Núm. 4, pp. 106-113

2015

  1. Do skin prick test and in vitro techniques diagnose sensitization to peach lipid transfer protein and profilin equally well in allergy to plant food and pollen?

    Journal of Investigational Allergology and Clinical Immunology, Vol. 25, Núm. 4, pp. 283-287

  2. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 70, Núm. 11, pp. 1393-1405

  3. The incidence of perioperative hypersensitivity reactions: A single-center, prospective, cohort study

    Anesthesia and Analgesia, Vol. 121, Núm. 1, pp. 117-123

2014

  1. Immunogenicity of peanut proteins containing poly(anhydride) nanoparticles

    Clinical and Vaccine Immunology, Vol. 21, Núm. 8, pp. 1106-1112

  2. Nanoparticle based-immunotherapy against allergy

    Immunotherapy, Vol. 6, Núm. 7, pp. 885-897

  3. The usefulness of plasma histamine and different tryptase cut-off points in the diagnosis of peranaesthetic hypersensitivity reactions

    Clinical and Experimental Allergy, Vol. 44, Núm. 2, pp. 270-277

2013

  1. Expression of the basophil-speciafic antibodies 2D7 and BB1 in patients with cutaneous mastocytosis

    Journal of Investigational Allergology and Clinical Immunology, Vol. 23, Núm. 6, pp. 392-397

2012

  1. Development of poly(anhydride) nanoparticles loaded with peanut proteins: The influence of preparation method on the immunogenic properties

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 82, Núm. 2, pp. 241-249

  2. Nanoparticles and microparticles for allergen immunotherapy

    Journal of investigational allergology & clinical immunology, Vol. 22, Núm. suppl. 1, pp. 7-15

  3. Nanoparticulate adjuvants and delivery systems for allergen immunotherapy

    Journal of Biomedicine and Biotechnology, Vol. 2012

  4. Nuevas formas farmacéuticas para el tratamiento de enfermedades alérgicas

    Anales del sistema sanitario de Navarra, Vol. 35, Núm. 1, pp. 41-51

  5. Performance of different in vitro techniques in the molecular diagnosis of peanut allergy

    Journal of Investigational Allergology and Clinical Immunology, Vol. 22, Núm. 7, pp. 508-513

  6. Pru p 3 acts as a strong sensitizer for peanut allergy in Spain

    Journal of Allergy and Clinical Immunology, Vol. 130, Núm. 6, pp. 1432-1434.e3

2011

  1. A new rapid desensitization protocol for chemotherapy agents

    Journal of Investigational Allergology and Clinical Immunology, Vol. 21, Núm. 2, pp. 108-112

  2. Can component-based microarray replace fluorescent enzimoimmunoassay in the diagnosis of grass and cypress pollen allergy?

    Clinical and Experimental Allergy, Vol. 41, Núm. 10, pp. 1440-1446

  3. Omalizumab is effective in nonautoimmune urticaria

    Journal of Allergy and Clinical Immunology, Vol. 127, Núm. 5, pp. 1300-1302

  4. The basophil activation test as a promising diagnostic tool in hypersensitivity to chironomid larvae

    Journal of Investigational Allergology and Clinical Immunology, Vol. 21, Núm. 2, pp. 158-159

2010

  1. Are basophils present in chronic urticaria lesions?

    Environmental and genetic actors in allergy and clinical immunology. Proceedings of the 27th environmental and genetic factors in allergy and clinical immunology; proceedings of the 27 symposium of the Collegium Internationale Allergologicum (CIA) (Pacini Editore Medicina), pp. 71-72